Merck Seeks Oxytrol “Partial” Switch As First Overactive Bladder OTC
This article was originally published in The Tan Sheet
You may also be interested in...
Merck Mines Mevacor Switch Data To Press FDA On Self-Selection Stance
Purchase decisions in OTC switch self-selection studies offer insight into subjects’ thinking “and how they might act in a real-world pharmacy setting,” Merck tells FDA in response to a draft guidance that says such decisions are driven by cost and are “an unreliable surrogate” for self-selection.
Overactive Bladder Category Switch Prospects Questioned By Indevus
Self-selection problems will likely complicate potential Rx-to-OTC switches in the overactive bladder (OAB) category, Indevus Pharmaceuticals execs maintained during an Aug. 9 third quarter earnings call
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.